ArticleInternational journal of obesity (2005)2026
Elevated serum glucosylsphingosine level in children with obesity: relation to plasma atherogenesis.
Article in International journal of obesity (2005), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlucosylsphingosine (Lyso-GL-1), a glycosphingolipid formed by glucosylceramide hydrolysis, is known to be increased in Gaucher disease. Recently, increased ceramides and sphingolipids have been implicated in obesity, insulin resistance, and atherogenesis. However, limited data exists on serum Lyso-GL-1 level in children with obesity and its relation with insulin resistance, lipid dysfunction, and atherogenesis. Hence, this study aimed to assess Lyso-GL-1 level among children with obesity and correlate it with biomarkers of insulin resistance and atherogenic index of plasma (AIP). METHODOLOGY: Sixty children with obesity with a mean age of 10.06 years (SDS ± 2.22) and 60 age- and sex-matched normal-weighed controls were assessed for anthropometric measures, mean blood pressure percentiles, serum Lyso-GL-1, glycated hemoglobin (HbA1c), fasting insulin, triglycerides, cholesterol, low-density (LDL-C) and high-density lipoprotein cholesterol (HDL-C) with calculation of the homeostatic model assessment of insulin resistance (HOMA-IR) and the AIP.
resultsChildren with obesity have significantly higher Lyso-GL-1 and AIP than controls. Lyso-GL-1 is significantly positively correlated with body mass index (BMI) z-score, waist/hip ratio z-score, systolic and diastolic blood pressure percentiles, LDL-C, HOMA-IR, and AIP (p < 0.05), being independently correlated with systolic blood pressure percentile, LDL-C, and AIP on multivariate regression analysis.
conclusionSerum Lyso-GL-1 is elevated in children with obesity, being closely correlated with hypertension, insulin resistance, and atherogenesis. This could provide a mechanistic insight on the role of Lyso-GL-1 in obesity and atherogenesis. Further studies are warranted to explore the potential role of Lyso-GL-1 as a biomarker and target for the prevention and treatment of obesity-related atherogenesis and insulin resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.